Apatinib developed by Hengrui Medicine inhibits the activities of VEGFR-2, c-Src, and c-Kit simultaneously and was approved for the treatment of advanced gastric cancer in October 2014.171 The multitarget inhibitor anlotinib is developed by Chiatai Tianqing.172 This anti-angiogenic agent has been used for the treatment of several malignant tumors including NSCLC, soft tissue sarcoma (STS), and small cell lung cancer (SCLC).173 These two drugs have been identified as orphan drugs by the FDA, but have not been launched in the United States. This evidence concerns the gene SRC and small cell lung carcinoma.